

University of Groningen

Genomic medicine in inflammatory bowel disease

Voskuil, Michiel

DOI:
[10.33612/diss.136307453](https://doi.org/10.33612/diss.136307453)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Voskuil, M. (2020). *Genomic medicine in inflammatory bowel disease*. University of Groningen.
<https://doi.org/10.33612/diss.136307453>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

GENOMIC MEDICINE IN INFLAMMATORY BOWEL DISEASE

Michiel Dirk Voskuil

Printing of this thesis was financially supported by the University of Groningen, the Graduate School of Medical Sciences of the University Medical Center Groningen, Noord Negentig, Takeda, Pfizer, Mylan, Norgine, TEVA Nederland, Tramedico, Ferring, and Dr. Falk Pharma Benelux B.V.

Printed by Ipskamp Printing
Enschede, the Netherlands

Design & layout Bianca Pijl, www.pijlldesign.nl
Groningen, the Netherlands

© Copyright: 2020 M.D. Voskuil, Groningen, the Netherlands

All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior written permission of the author, or when appropriate, of the publishers of the publications included in this thesis.



rijksuniversiteit
groningen

GENOMIC MEDICINE IN INFLAMMATORY BOWEL DISEASE

Proefschrift

ter verkrijging van de graad van doctor
aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties

De openbare verdediging zal plaatsvinden op

maandag 9 november 2020 om 14:30 uur

door

Michiel Dirk Voskuil

geboren op 10 september 1991
te Nieuwegein

Promotor

Prof. dr. R.K. Weersma

Copromotor

Dr. E.A.M. Festen

Beoordelingscommissie

Prof. dr. H. Bootsma

Prof. dr. G. Bouma

Prof. dr. R.H. Sijmons

Voor mijn ouders

Paranimfen

Drs. F.J. Voskuil

Dr. S.J. de Jongh

Table of contents

	Introduction	
Chapter 1	General introduction and outline of the thesis	11
	Part I – Aetiology	
Chapter 2	The genetic background of inflammatory bowel disease: from correlation to causality <i>Journal of Pathology 2017</i>	21
Chapter 3	Single cell RNA sequencing of blood and ileal T cells from patients with Crohn's disease reveals tissue-specific characteristics and drug targets <i>Gastroenterology 2019 (modified version)</i>	47
	Part II – Disease course	
Chapter 4	Genetic risk scores identify genetic aetiology of inflammatory bowel disease phenotypes <i>Submitted</i>	75
	Part III – Therapy	
Chapter 5	Predicting side effects for patients with inflammatory bowel disease: the promise of pharmacogenetics <i>World Journal of Gastroenterology 2019</i>	93
Chapter 6	Association of genetic variants in <i>NUDT15</i> with thiopurine-induced myelosuppression in patients with inflammatory bowel disease <i>JAMA 2019</i>	109
Chapter 7	Exome-wide association study identifies a frameshift mutation in <i>ZNF516</i> as genetic determinant of thiopurine-induced hepatotoxicity in patients with inflammatory bowel disease <i>In progress</i>	135

Table of contents

Chapter 8	Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease <i>Alimentary Pharmacology and Therapeutics 2020</i>	157
COVID-19 and IBD		
Chapter 9	TNF α -antagonist use and mucosal inflammation are associated with increased intestinal expression of SARS-CoV-2 host protease <i>TMPRSS2</i> in patients with inflammatory bowel disease <i>Gastroenterology 2020</i>	179
Discussion		
Chapter 10	Summary	189
Chapter 11	General discussion and future perspectives	195
Appendices		
	Summary in Dutch	219
	List of publications	225
	Curriculum Vitae	233
	Dankwoord	237

INTRODUCTION